An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.

[1]  M. Andreeff,et al.  Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. , 2022, The Lancet. Haematology.

[2]  S. Pavletic,et al.  Meaningful response criteria for myelodysplastic syndromes , 2021, British journal of haematology.

[3]  L. Pleyer,et al.  Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. , 2021, The Lancet. Haematology.

[4]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[5]  L. Pleyer,et al.  Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group , 2019, Blood.

[6]  D. Steensma,et al.  Rethinking clinical trial endpoints in myelodysplastic syndromes , 2019, Leukemia.

[7]  C. Bloomfield,et al.  Time to repeal and replace response criteria for acute myeloid leukemia? , 2018, Blood reviews.

[8]  L. Pleyer,et al.  Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group , 2017, International journal of molecular sciences.

[9]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[10]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.